Roger S. Lo

Biochemistry, Genetics and Molecular BiologyComputer ScienceMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy”.

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.07.023

N/A

3.9DataRank · unranked

135 citations

Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang +16 more

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100426

N/A

3.2DataRank · unranked

99 citations

Joshua D. Horton, Sixue Liu, Kent Armeson, John M. Kaczmar, Megan M. Wyatt +21 more

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100411

N/A

1.9DataRank · unranked

57 citations

Hannah M. Knochelmann, Shirley H. Lomeli, Aayoung Hong, Mary S. Richardson, Zhentao Yang +14 more

TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders

Cell(2000)10.1016/s0092-8674(00)00121-5

N/A

1.2DataRank · unranked

2368 citations

Stacy W. Blain, Roger S. Lo, Joan Massagué

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more

Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0936

N/A

0DataRank · unranked

78 citations

Jenna K. Minami, Arthur Huang, Siavash R. Dehkordi, Shirley H. Lomeli, Jens Luebeck +26 more

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects

PLoS ONE(2021)10.1371/journal.pone.0252597

N/A

0DataRank · unranked

18 citations

Yining Liu, Lu Sun, Willy Hugo, Robert Dimatteo, Rong Huang +10 more

Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH

Nature Genetics(2022)10.1038/s41588-022-01190-0

N/A

0DataRank · unranked

125 citations

Jens Luebeck, Siavash R. Dehkordi, Caterina I. Colón, Rui Li, Ivy Tsz-Lo Wong +21 more

Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1463

N/A

0DataRank · unranked

39 citations

Yan Wang, Sixue Liu, Weixian Deng, Shirley H. Lomeli, Gatien Moriceau +4 more

Multi-organ landscape of therapy-resistant melanoma

Nature Medicine(2023)10.1038/s41591-023-02304-9

N/A

0DataRank · unranked

31 citations

Prashanthi Dharanipragada, Shirley H. Lomeli, Yan Wang, Xiao Zhang, Zhentao Yang +9 more

The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance

Cell(2024)10.1016/j.cell.2024.08.001

N/A

0DataRank · unranked

56 citations

Xiao Zhang, Mingming Wu, Yan Wang, Jose Espejo Valle-Inclán, Qing Hu +8 more

Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors

Immunity(2025)10.1016/j.immuni.2025.10.001

N/A

0DataRank · unranked

3 citations

Shiyue Yang, Zhentao Yang, Jianfeng Fan, Shirley H. Lomeli, Prashanthi Dharanipragada +12 more

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Nature Medicine(2020)10.1038/s41591-020-0818-3

N/A

0DataRank · unranked

118 citations

Howard H. Yang, Romina E. Araya, Rajaâ El Meskini, Helen Michael, Suman K. Vodnala +20 more

SPRED1 deletion confers resistance to MAPK inhibition in melanoma

The Journal of Experimental Medicine(2020)10.1084/jem.20201097

N/A

0DataRank · unranked

31 citations

Sixue Liu, Gatien Moriceau, Roger S. Lo, Leonard I. Zon, Julien Ablain

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

UNC Libraries(2020)10.17615/73y8-rn80

N/A

0DataRank · unranked

7 citations

Gatien Moriceau, Robert Damoiseaux, Roger S. Lo, Lu Sun, Aayoung Hong +5 more

Trying for a BRAF Slam Dunk

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0231

N/A

0DataRank · unranked

3 citations

Roger S. Lo, Antoni Ribas